Dr. Ruth O'Regan, M.D., is the Chair of Medicine and Charles A. Dewey Professor at the University of Rochester. She additionally serves as Physician-in-Chief of Strong Memorial Hospital and as Associate Director of Education and Mentoring at the Wilmot Cancer Institute at University of Rochester.

She previously was Division Chief of Hematology, Medical Oncology and Palliative Care in the Department of Medicine and as Deputy Director at the Carbone Cancer Center at the University of Wisconsin School of Medicine and Public Health (UWSMPH). She served as Chief Scientific officer of the Big Ten Cancer Research Consortium guiding the research and scientific mission of the consortium and as Vice-Chair of the National Comprehensive Cancer Network Board of Directors. Prior to joining the faculty at UWSMPH she was Director of the Glenn Family Breast Cancer Program at the Winship Cancer Institute and as Vice-Chair for Education and Director of the Hematology Oncology Fellowship program in the Department of Hematology and Medical Oncology at Emory University. She additionally served as Chief of Hematology and Medical Oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital.

Dr. O'Regan earned her Medical Degree from University College, Dublin, Ireland and completed her Internal Medicine residency at the Medical College of Wisconsin and her Hematology/Oncology fellowship at Northwestern University.

Her research program focuses on identifying mechanisms of resistance to breast-cancer therapies and on the development of new therapies with a specific focus on triple negative breast cancer.

Faculty Appointments

Professor - Department of Medicine (SMD)

Chair - Department of Medicine (SMD)

Charles Ayrault Dewey Professorship of Medicine - Department of Medicine (SMD)

Professor - Cancer Center - Joint

Connect with Ruth M. O'Regan, M.D.

@oreganruth

Credentials

Residency & Fellowship

Residency, Internal Medicine, McGaw Medical Center of Northwestern University. 1998 - 1999

Fellowship, Hematology & Oncology, McGaw Medical Center of Northwestern University. 1995 - 1998

Internship, Internal Medicine, Medical College of Wisconsin. 1994 - 1995

Fellowship, Oncology, Mater Misericordiae University Hospital (Ireland). 1992 - 1994

Fellowship, Internal Medicine, Mease Hospital Dunedin. 1991 - 1992

Residency, Internal Medicine, Mater Misericordiae University Hospital (Ireland). 1988 - 1991

Education

MBBCH | University College Dublin (Republic of Ireland). 1988

Research

Clinical Trials

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers Hoosier Cancer Research Network BRE17-141

Lead Researcher: Ruth M O'Regan

Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A bre...

A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024,A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024

Lead Researcher: Ruth M O'Regan

This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.

Publications

Journal Articles

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.

Tolaney SM, Kalinsky K, Kaklamani V, D'Adamo DR, Aktan G, Tsai ML, O'Regan RM, Kaufman PA, Wilks ST, Andreopoulou E, Patt DA, Yuan Y, Wang G, Savulsky C, Xing D, Kleynerman E, Karantza V, Diab S

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2021 June 127 (11):3061-3068. Epub 03/16/2021.

Benchmarks for Academic Oncology Faculty.

Anthony L, Atweh G, Bhatia R, Carey LA, Chang JC, Edelman MJ, Kantoff PW, Markham MJ, Messersmith W, Nelson EL, Oettel K, O'Regan R, Verschraegen CF, Vose JM

JCO oncology practice.. 2021 March 17 (3):e440-e444. Epub 09/30/2020.

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.

Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM

Breast cancer research and treatment.. 2020 October 183 (3):617-627. Epub 07/22/2020.

Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+?and FOXP3+?immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.

Zhao J, Meisel J, Guo Y, Nahta R, Hsieh KL, Peng L, Wei Z, O'Regan R, Li X

Breast cancer research and treatment.. 2020 October 183 (3):599-606. Epub 07/26/2020.

Progress in breast cancer research amid the COVID-19 gloom.

Khuri FR, O'Regan RM

Cancer.. 2020 August 15126 Suppl 16 :3809-3810. Epub 1900 01 01.

Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer.

Anandan A, Sharifi M, O'Regan R

Current treatment options in oncology.. 2020 August 1521 (10):84. Epub 08/15/2020.

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 August 1038 (23):2610-2619. Epub 05/29/2020.

Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.

Sharifi MN, Anandan A, Grogan P, O'Regan RM

Cancer.. 2020 August 1126 (15):3400-3416. Epub 05/19/2020.

Implementation of a chemotherapy stewardship process.

Hennes ER, Reed M, Mably M, Jared J, Bergsbaken JJ, Deming D, Callander N, O'Regan R

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.. 2020 July 2377 (15):1243-1248. Epub 1900 01 01.

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R

Journal of the National Comprehensive Cancer Network : JNCCN.. 2020 April 18 (4):452-478. Epub 1900 01 01.

The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics.

Zhang S, O'Regan R, Xu W

Cancer.. 2020 March 1126 (5):939-948. Epub 12/23/2019.

Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.

Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X

Clinical breast cancer.. 2020 February 20 (1):19-24. Epub 09/18/2019.

Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling.

Fatima I, El-Ayachi I, Playa HC, Alva-Ornelas JA, Khalid AB, Kuenzinger WL, Wend P, Pence JC, Brakefield L, Krutilina RI, Johnson DL, O'Regan RM, Seewaldt V, Seagroves TN, Krum SA, Miranda-Carboni GA

Cancers.. 2019 December 1711 (12)Epub 12/17/2019.

Race, breast cancer, and prognosis: Where biology is queen?

Meisel JL, O'Regan RM

Cancer.. 2019 September 15125 (18):3104-3106. Epub 06/17/2019.

ER/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER/HER2 Breast Cancer.

Arciero CA, Guo Y, Jiang R, Behera M, O'Regan R, Peng L, Li X

Clinical breast cancer.. 2019 August 19 (4):236-245. Epub 02/14/2019.

Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.

Paplomata E, Zelnak A, Santa-Maria CA, Liu Y, Gogineni K, Li X, Moreno CS, Chen Z, Kaklamani V, O'Regan RM

Clinical breast cancer.. 2019 June 19 (3):188-196. Epub 01/03/2019.

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.

El Ayachi I, Fatima I, Wend P, Alva-Ornelas JA, Runke S, Kuenzinger WL, Silva J, Silva W, Gray JK, Lehr S, Barch HC, Krutilina RI, White AC, Cardiff R, Yee LD, Yang L, O'Regan RM, Lowry WE, Seagroves TN, Seewaldt V, Krum SA, Miranda-Carboni GA

Cancer research.. 2019 March 179 (5):982-993. Epub 12/18/2018.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R

Journal of the National Comprehensive Cancer Network : JNCCN.. 2019 February 17 (2):118-126. Epub 1900 01 01.

Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?

Kalinsky K, O'Regan RM

Cancer.. 2019 January 15125 (2):177-180. Epub 11/02/2018.

Social media and clinical trials: The pros and cons gain context when the patient is at the center.

Thompson MA, O'Regan RM

Cancer.. 2018 December 15124 (24):4618-4621. Epub 10/19/2018.

Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.

Meisel J, Zhang C, Neely C, Mendoza P, You S, Han T, Liu Y, Sahin AA, O'Regan R, Li X

Clinical breast cancer.. 2018 October 18 (5):347-352. Epub 12/14/2017.

Targeting forkhead box M1 transcription factor in breast cancer.

O'Regan RM, Nahta R

Biochemical pharmacology.. 2018 August 154 :407-413. Epub 05/31/2018.

Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.

Denduluri N, Miller K, O'Regan RM

American Society of Clinical Oncology educational book. 2018 May 2338 :47-55. Epub 1900 01 01.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA

Journal of the National Comprehensive Cancer Network : JNCCN.. 2018 March 16 (3):310-320. Epub 1900 01 01.

Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.

Miller-Kleinhenz J, Guo X, Qian W, Zhou H, Bozeman EN, Zhu L, Ji X, Wang YA, Styblo T, O'Regan R, Mao H, Yang L

Biomaterials.. 2018 January 152 :47-62. Epub 10/21/2017.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Cs?szi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T

The Lancet. Oncology.. 2018 January 19 (1):87-100. Epub 12/07/2017.

Adjuvant Endocrine Therapy.

Shah R, O'Regan RM

Cancer treatment and research.. 2018 173 :15-29. Epub 1900 01 01.

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.

Arciero CA, Yang J, Peng L, Ward KC, O'Regan R, Sahin AA, Li X

Breast cancer research and treatment.. 2017 December 166 (3):743-755. Epub 08/30/2017.

Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.

Li X, Yang J, Krishnamurti U, Huo L, Ward KC, O'Regan R, Peng L

Clinical breast cancer.. 2017 August 17 (5):356-366. Epub 04/28/2017.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Journal of the National Comprehensive Cancer Network : JNCCN.. 2017 April 15 (4):433-451. Epub 1900 01 01.

AR Signaling in Breast Cancer.

Rahim B, O'Regan R

Cancers.. 2017 February 249 (3)Epub 02/24/2017.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ

Investigational new drugs.. 2017 February 35 (1):87-94. Epub 11/08/2016.

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.

Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL

Breast cancer research and treatment.. 2017 January 161 (2):279-287. Epub 11/25/2016.

Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.

Tevaarwerk AJ, Wisinski KB, O'Regan RM

Journal of oncology practice. 2016 November 12 (11):1148-1156. Epub 1900 01 01.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 June 2034 (18):2115-24. Epub 04/18/2016.

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O'Regan R, Aneja R

American journal of clinical pathology.. 2016 June 145 (6):871-8. Epub 06/12/2016.

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers.

Strauss WM, Carter C, Simmons J, Klem E, Goodman N, Vahidi B, Romero J, Masterman-Smith M, O'Regan R, Gogineni K, Schwartzberg L, Austin LK, Dempsey PW, Cristofanilli M

Oncotarget.. 2016 May 37 (18):26724-38. Epub 1900 01 01.

Role of the androgen receptor in triple-negative breast cancer.

Rampurwala M, Wisinski KB, O'Regan R

Clinical advances in hematology & oncology : H&O.. 2016 March 14 (3):186-93. Epub 1900 01 01.

Optimizing Endocrine Therapy for Breast Cancer.

Zelnak AB, O'Regan RM

Journal of the National Comprehensive Cancer Network : JNCCN.. 2015 August 13 (8):e56-64. Epub 1900 01 01.

Triple-negative breast cancer in African-American women: disparities versus biology.

Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL

Nature reviews. Cancer.. 2015 April 15 (4):248-54. Epub 02/12/2015.

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.

Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E, Nagaraju GP, Havel L, Marcus A, Nahta R, O'Regan R

Oncotarget.. 2015 March 106 (7):4757-72. Epub 1900 01 01.

Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?

Paplomata E, Nahta R, O'Regan RM

Cancer.. 2015 February 15121 (4):517-26. Epub 10/24/2014.

High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.

Zelnak AB, Nikolinakos P, Srinivasiah J, Jonas W, Pippas A, Liu Y, Li X, Torres M, O'Regan RM,

Clinical breast cancer.. 2015 February 15 (1):31-6. Epub 06/24/2014.

Breast cancer screening: time for rational discourse.

Brawley OW, O'Regan RM

Cancer.. 2014 September 15120 (18):2800-2. Epub 06/12/2014.

Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer.

Liu D, Xiong H, Ellis AE, Northrup NC, Rodriguez CO, O'Regan RM, Dalton S, Zhao S

Cancer research.. 2014 September 1574 (18):5045-56. Epub 07/31/2014.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 August 132 (22):2311-7. Epub 06/16/2014.

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.

Paplomata E, O'Regan R

Therapeutic advances in medical oncology.. 2014 July 6 (4):154-66. Epub 1900 01 01.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L

The Lancet. Oncology.. 2014 May 15 (6):580-91. Epub 04/14/2014.

Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.

Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, O'Regan R

Patient education and counseling.. 2014 April 95 (1):98-103. Epub 01/10/2014.

A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.

Xu J, Agyemang S, Qin Y, Aysola K, Giles M, Oprea G, O'Regan RM, Partridge EE, Harris-Hooker S, Rice VM, Reddy ES, Rao VN

Enliven. Challenges in cancer detection and therapy.. 2014 1 (1)Epub 1900 01 01.

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.

Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, André F

Breast cancer research and treatment.. 2013 October 141 (3):437-46. Epub 10/08/2013.

Everolimus: side effect profile and management of toxicities in breast cancer.

Paplomata E, Zelnak A, O'Regan R

Breast cancer research and treatment.. 2013 August 140 (3):453-62. Epub 08/02/2013.

Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis.

Hagen KR, Zeng X, Lee MY, Tucker Kahn S, Harrison Pitner MK, Zaky SS, Liu Y, O'Regan RM, Deng X, Saavedra HI

Cell division. 2013 July 258 (1):10. Epub 07/25/2013.

Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.

Zelnak AB, Styblo TM, Rizzo M, Gabram SG, Wood WC, Harichand-Herdt S, Kim S, Liu Y, O'Regan RM,

Clinical breast cancer.. 2013 June 13 (3):173-9. Epub 01/16/2013.

Genomic subtypes in choosing adjuvant therapy for breast cancer.

Zelnak AB, O'Regan RM

Oncology.. 2013 March 27 (3):204-10. Epub 1900 01 01.

Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008.

Habtes I, Friedman D, Raskind-Hood C, Adams K, Becker ER, D'Orsi C, Birdsong G, Gundry K, O'Regan R, Gabram SG

Cancer.. 2013 February 1119 (3):481-7. Epub 08/01/2012.

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.

Paplomata E, O'Regan R

Therapeutics and clinical risk management.. 2013 9 :27-36. Epub 01/14/2013.

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer.

Marcus DM, Switchenko JM, Prabhu R, O'Regan R, Zelnak A, Fasola C, Mister D, Torres MA

Frontiers in oncology.. 2013 3 :317. Epub 12/27/2013.

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 November 2030 (33):4071-6. Epub 07/23/2012.

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.

Nahta R, O'Regan RM

Breast cancer research and treatment.. 2012 August 135 (1):39-48. Epub 04/20/2012.

Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in breast carcinoma.

Zhao P, Nairn AV, Hester S, Moremen KW, O'Regan RM, Oprea G, Wells L, Pierce M, Abbott KL

The Journal of biological chemistry.. 2012 July 20287 (30):25230-40. Epub 05/31/2012.

The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation.

Prabhu R, Godette K, Carlson G, Losken A, Gabram S, Fasola C, O'Regan R, Zelnak A, Torres M

International journal of radiation oncology, biology, physics.. 2012 March 1582 (4):e587-93. Epub 12/22/2011.

Emerging nontaxane therapies for metastatic breast cancer.

O'Regan R

Clinical advances in hematology & oncology : H&O.. 2012 March 10 (3):187-9. Epub 1900 01 01.

21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.

Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM

Cancer.. 2012 February 1118 (3):788-96. Epub 06/30/2011.

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.

Gayle SS, Arnold SL, O'Regan RM, Nahta R

Anti-cancer agents in medicinal chemistry.. 2012 February 12 (2):151-62. Epub 1900 01 01.

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.

Mitri Z, Constantine T, O'Regan R

Chemotherapy research and practice. 2012 2012 :743193. Epub 12/20/2012.

Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?

Andic F, Godette K, O'Regan R, Zelnak A, Liu T, Rizzo M, Gabram S, Torres M

Cancer.. 2011 December 15117 (24):5485-92. Epub 06/20/2011.

The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.

Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, O'Regan RM, Yu ES, Yu DS, Landry JC

Annals of surgical oncology.. 2011 October 18 (10):2858-65. Epub 03/26/2011.

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.

Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O'Regan RM

Molecular cancer therapeutics.. 2011 August 10 (8):1460-9. Epub 06/20/2011.

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.

O'Regan R, Hawk NN

Expert opinion on therapeutic targets.. 2011 July 15 (7):859-72. Epub 04/08/2011.

Adjuvant anthracyclines: time for a change of heart?

O'Regan R

Oncology.. 2011 February 25 (2):140, 142. Epub 1900 01 01.

Improving on national quality indicators of breast cancer care in a large public hospital as a means to decrease disparities for African American women.

Rizzo M, Bumpers H, Okoli J, Senior-Crosby D, O'Regan R, Zelnak A, Pan L, Mosunjac M, Patterson SG, Gabram SG

Annals of surgical oncology.. 2011 January 18 (1):34-9. Epub 07/13/2010.

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.

Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2010 December 128 (34):5110-5. Epub 10/25/2010.

Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone.

Harichand-Herdt S, O'regan RM

American journal of clinical oncology.. 2010 December 33 (6):561-7. Epub 1900 01 01.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM

Clinical breast cancer.. 2010 November 10 Suppl 3 :S72-8. Epub 1900 01 01.

Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.

Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O'Regan RM

Breast cancer research and treatment.. 2010 August 123 (1):139-47. Epub 11/18/2009.

Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.

Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW

Cancer.. 2010 June 1116 (11):2549-59. Epub 1900 01 01.

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R

Cancer chemotherapy and pharmacology.. 2010 March 65 (4):697-706. Epub 07/28/2009.

Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.

Kaklamani VG, Cianfrocca M, Ciccone J, Kindy K, Rademaker A, Wiley EL, Gradishar W, O'Regan RM

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.. 2010 March 15 (2):191-3. Epub 1900 01 01.

Using National Quality Forum breast cancer indicators to measure quality of care for patients in an AVON comprehensive breast center.

Iyengar R, Lund MJ, Lamson P, Holmes L, Rizzo M, Bumpers H, Okoli J, Senior-Crosby D, O'Regan R, Gabram SG

The breast journal.. 2010 16 (3):240-4. Epub 04/12/2010.

Adjuvant chemotherapy: how much is enough?

O'Regan RM

The Lancet. Oncology.. 2009 December 10 (12):1132-3. Epub 11/10/2009.

Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.

Rowe DL, Ozbay T, O'Regan RM, Nahta R

Breast cancer : basic and clinical research.. 2009 September 23 :61-75. Epub 09/02/2009.

Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer.

Rizzo M, Lund MJ, Mosunjac M, Bumpers H, Holmes L, O'Regan R, Brawley OW, Gabram S

Cancer.. 2009 July 1115 (13):3009-15. Epub 1900 01 01.

Endocrine therapy for the treatment of postmenopausal women with breast cancer.

Harichand-Herdt S, Zelnak A, O'Regan R

Expert review of anticancer therapy.. 2009 February 9 (2):187-98. Epub 1900 01 01.

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW

Breast cancer research and treatment.. 2009 January 113 (2):357-70. Epub 03/07/2008.

Inorganic nanoparticles for predictive oncology of breast cancer.

Yezhelyev M, Yacoub R, O'Regan R

Nanomedicine.. 2009 January 4 (1):83-103. Epub 1900 01 01.

Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.

Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, Sharma D

Cancer research.. 2008 December 168 (23):9712-22. Epub 1900 01 01.

Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging.

Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X

Journal of the American Chemical Society.. 2008 July 16130 (28):9006-12. Epub 06/21/2008.

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.

Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM

Cancer research.. 2008 April 168 (7):2479-88. Epub 1900 01 01.

Targeted glycoproteomic identification of biomarkers for human breast carcinoma.

Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, Wells L, Tiemeyer M, Pierce M

Journal of proteome research.. 2008 April 7 (4):1470-80. Epub 02/14/2008.

Adjuvant hormonal therapy for early-stage breast cancer.

Zelnak AB, O'Regan R

Cancer treatment and research.. 2008 141 :63-78. Epub 1900 01 01.

A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.

Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ

Cancer investigation.. 2007 December 25 (8):733-7. Epub 10/18/2007.

Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells.

Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, Wood WC, Lee HY, Yang L

Molecular pharmacology.. 2007 January 71 (1):101-11. Epub 10/11/2006.

Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry.

Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, Chung LW, Petros JA, O'Regan RM, Yezhelyev MV, Simons JW, Wang MD, Nie S

Nature protocols.. 2007 2 (5):1152-65. Epub 1900 01 01.

Targeting angiogenesis in advanced breast cancer.

Zelnak AB, O'Regan RM

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.. 2007 21 (4):209-14. Epub 1900 01 01.

Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation.

Seleverstov O, Zabirnyk O, Zscharnack M, Bulavina L, Nowicki M, Heinrich JM, Yezhelyev M, Emmrich F, O'Regan R, Bader A

Nano letters.. 2006 December 6 (12):2826-32. Epub 1900 01 01.

Emerging use of nanoparticles in diagnosis and treatment of breast cancer.

Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM

The Lancet. Oncology.. 2006 August 7 (8):657-67. Epub 1900 01 01.

Chemoprevention of breast cancer.

O'Regan RM

Lancet.. 2006 April 29367 (9520):1382-3. Epub 1900 01 01.

Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.

O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2006 April 112 (7 Pt 1):2255-63. Epub 1900 01 01.

Selection of optimal adjuvant endocrine therapy for early-stage breast cancer.

Al-Hajj A, O'Regan R

Current treatment options in oncology.. 2006 March 7 (2):153-65. Epub 1900 01 01.

Review: bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases.

O'Regan R

ACP journal club.. 2006 144 (2):39. Epub 1900 01 01.

Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.

O'Regan RM, Von Roenn JH, Carlson RW, Malik U, Sparano JA, Staradub V, Khan S, Jovanovic B, Morrow M, Gradishar WJ

Clinical breast cancer.. 2005 June 6 (2):163-8. Epub 1900 01 01.

Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.

Kudachadkar R, O'Regan RM

CA: a cancer journal for clinicians.. 2005 55 (3):145-63. Epub 1900 01 01.

Biomedical nanotechnology for molecular imaging, profiling, and drug targeting.

Kim G, O'regan R, Nie S

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society.. 2005 2006 :714-6. Epub 1900 01 01.

Do tumors detected by mammography screening have a favorable prognosis?

O'Regan RM

JAMA.. 2004 September 1292 (9):1062-3. Epub 1900 01 01.

New targeted therapies in breast cancer.

Kaklamani V, O'Regan RM

Seminars in oncology.. 2004 April 31 (2 Suppl 4):20-5. Epub 1900 01 01.

Chemoprevention of breast cancer.

Zelnak AB, O'Regan RM

Current problems in cancer.. 2004 28 (4):201-17. Epub 1900 01 01.

Right atrial and ventricular thrombus infiltrated with osteoblastic osteosarcoma.

Shah AP, Parmar S, O'Regan R

Journal of cardiovascular pharmacology and therapeutics.. 2003 December 8 (4):307-11. Epub 1900 01 01.

Progress in systemic adjuvant therapy of early-stage breast cancer.

Gradishar WJ, O'Regan RM

International journal of clinical oncology.. 2003 August 8 (4):239-47. Epub 1900 01 01.

Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.

Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2002 June 8 (6):1995-2001. Epub 1900 01 01.

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.

O'Regan RM, Jordan VC

The Lancet. Oncology.. 2002 April 3 (4):207-14. Epub 1900 01 01.

Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.

O'Regan RM, Gajdos C, Dardes RC, De Los Reyes A, Park W, Rademaker AW, Jordan VC

Journal of the National Cancer Institute.. 2002 February 2094 (4):274-83. Epub 1900 01 01.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.